| Mark W. Noel |
Mark W. Noel is currently the VP-Technology Management & Intellectual Property at Curis, Inc. He was previously the Deputy Director at the National Cancer Institute from 1993 to 1998. He then worked as the Director-Regulatory Affairs Department at Gist-Brocades NV before becoming the Vice President-Customer Relations at Gene Logic, Inc. from 1998 to 2001. Mr. Noel received his undergraduate degree from the University of Maryland. |
| Jonathan B. Zung |
Jonathan B. Zung is currently the Chief Development Officer at Curis, Inc. He previously held positions as Chairman at Clinical Data Interchange Standards Consortium, Inc., Group President-Clinical Development at Labcorp Drug Development, Inc., VP & Head-Global Clinical Sciences & Operations at UCB SA, and President-Sponsor & CRO Programs at WIRB- Copernicus Group, Inc. He also served as the Chief Development Officer at Evelo Biosciences, Inc. Additionally, he holds a doctorate degree from Emory University and an undergraduate degree from Florida Institute of Technology, Inc. |
| Reinhard von Roemeling |
Reinhard von Roemeling is currently the Senior Vice President-Clinical Development at Curis, Inc. He was previously the Global Head-Research & Development at HUYA Bioscience International LLC. Dr. von Roemeling holds a doctorate degree from Johann Wolfgang Goethe-Universität Frankfurt am Main. |
| Kimberly Steinmann |
Kimberly Steinmann is currently the Vice President-Clinical Development at Curis, Inc. Her former job was as the Executive Director-Medical at Grifols, Inc. She received her undergraduate and doctorate degrees from St. Louis University. |
| Robert E. Martell |
Robert E. Martell was the founder of Epi-Cure Pharmaceuticals, Inc. (founded in 2016) where he held the title of President, Secretary, Treasurer & Director from 2016 to 2018. He is currently working as a Director at Indaptus Therapeutics, Inc. since 2023 and as the Chief Scientific Officer at Curis, Inc. since 2011. Additionally, he is a Member of the American Society of Clinical Oncology, Inc., a Member of the American Association for Cancer Research, and a Professor at Tufts University School of Medicine. In the past, he worked as the Director-Oncology Global Clinical Research at Bristol Myers Squibb Co. from 2002 to 2005, Deputy Director-Pharmaceutical Division at Bayer Corp. from 2000 to 2002, Deputy Director-Medical Science Unit at Bayer Pharmaceuticals Corp., Director-Neely Center at Clinical Cancer Research, Chief Medical Officer at Tesaro, Inc. from 2012 to 2015, Chief Medical Officer & Vice President at Mirati Therapeutics, Inc. from 2005 to 2009, Associate Chief-Hematology & Oncology Division at Tufts Medical Center, Inc., Associate Professor at Tufts Medical Center, Inc. from 2009 to 2012, Assistant Professor at Duke University Medical Center from 1998 to 2000, and Assistant Clinical Professor at Yale School of Medicine from 2001 to 2005. He obtained a doctorate degree from Wayne State University (Michigan) and the University of Michigan, and an undergraduate degree from Kalamazoo College. |
| Martyn D. Greenacre |
Martyn D. Greenacre's current job(s) include Chairman at Curis, Inc., Chairman at Life Mist Technologies, Inc., and Director at Formula Pharmaceuticals, Inc. Mr. Greenacre's former job(s) include President & Chief Executive Officer at Zynaxis, Inc., Chief Executive Officer & Director at Delsys Pharmaceutical Corp., Chairman at Life Mist LLC, Chairman at Beijing Med-Pharm Corp., Director & Chairman-European Operations at Smithkline Beecham Pharmaceuticals (India) Ltd., Chairman at BMP Sunstone Corp., Director at Cephalon, Inc., Director at Creative Biomolecules, Inc., Director at Orchestra Therapeutics, Inc., Director at Acusphere, Inc., Director at NeoStem, Inc., Director at Caladrius Biosciences, Inc., Member-Executive Committee at Applera Corp., and Senior Advisor at Arsenal Capital Management LP. Mr. Greenacre's education history includes an MBA from Harvard Business School and an undergraduate degree from Harvard College. |
| James E. Dentzer |
James E. Dentzer is currently the President, Chief Executive Officer & Director at Curis, Inc. and an Independent Director at Imunon, Inc. He previously held positions as the Chief Financial Officer-DuPont Flooring Systems at EIDP, Inc., Controller at Biogen, Inc., Chief Financial Officer at Amicus Therapeutics, Inc., Chief Financial Officer at Dicerna Pharmaceuticals, Inc., and Chief Financial Officer at Valeritas, Inc. Mr. Dentzer obtained his undergraduate degree from Boston College and his MBA from The University of Chicago Booth School of Business. |
| Marc Rubin |
Marc Rubin is currently an Independent Director at Curis, Inc., an Independent Director at Galectin Therapeutics, Inc., a Director at Soricimed Biopharma, Inc., and a Director at The Rogosin Institute, Inc. He previously served as the President & Chief Executive Officer at Titan Pharmaceuticals, Inc. from 2007 to 2009. He was also a Director at Medarex, Inc. from 2007 to 2009 and at Surface Logix LLC from 2005 to 2011. Additionally, he held positions as the Head-Global Research & Development at Bayer Schering Pharma AG from 2006 to 2007 and at Bayer Pharma AG from 2007 to 2007. Dr. Rubin has a doctorate degree from Weill Cornell Medical College, which he obtained in 1980. |
| John A. Hohneker |
John A. Hohneker is currently an Independent Director at Curis, Inc., a Director at BioTheryX, Inc., a Director at Torque Therapeutics, Inc., a Director at Trishula Therapeutics, Inc., and a Director at Sonata Therapeutics, Inc. He previously served as the President, Chief Executive Officer & Director at Anokion SA and Kanyos Bio, Inc. He was also the Head of Research & Development at FORMA Therapeutics, Inc. and the SVP & Global Head-Development & Immunology at Novartis AG. Hohneker holds a doctorate from the University of Medicine & Dentistry of New Jersey and Robert Wood Johnson Medical School, as well as an undergraduate degree from Gettysburg College. |
| Kenneth I. Kaitin |
Kenneth I. Kaitin is currently serving as an Independent Director at Curis, Inc., as well as holding director positions at Bio-Tree Systems, Inc., Centerphase Solutions, Inc., and QCDx LLC. Previously, he served as a Director at Phase Forward, Inc. from 2007 to 2010. He also held director positions at New England Healthcare Institute and Erevnos Corp. Additionally, Dr. Kaitin served as the Director of Drug Development Study at Tufts Center for the Study of Drug Development from 1998 to 2020. He was the President of Drug Information Association from 1997 to 1998 and a Research Professor at Tufts University School of Medicine from 2008 to 2014. Dr. Kaitin obtained his graduate and doctorate degrees from Rochester Christian University and his undergraduate degree from Cornell University. |
